Eris Lifesciences Ltd.

“Eris Lifesciences is a genuine chronic-care franchise with a prescriber-loyalty moat, Torrent-level margins, and a structurally growing Indian market, but three successive leveraged acquisitions have compressed ROIC to near-WACC, loaded the balance sheet with ~₹2,000 crore of goodwill, and pushed net leverage to 2–3x EBITDA. At 27x forward earnings, the market is pricing near-perfect integration execution — a bet that Eris's own track record does not yet warrant. The business is not broken, but the margin of safety is absent. A patient investor should track for an entry below ₹1,100 or wait for integration evidence (ROCE recovering above 20%, net leverage below 1.5x) before sizing meaningfully.”